The FDA has approved the supplemental biologics license application for pegloticase, expanding the drug’s label to include co-administration with methotrexate in patients with uncontrolled gout, according to a press release.
“Today’s approval for Krystexxa with methotrexate is the culmination of more than 5 years of effort and demonstrates Horizon’s commitment to working together with the gout community to improve the patient experience and outcomes,” Elizabeth H.Z. Thompson, PhD, executive vice president of research and development at Horizon Therapeutics, said